Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 12/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30766052 | 0.93 | KLK7 (0.42) | ELANEBCHEKLK7KLK5 | |
| SCHEMBL30765978 | 0.91 | ELANE (0.41) | ELANEBCHENPC1RAB9AKDM4E | |
| SCHEMBL30765950 | 0.88 | BCHE (0.38) | SLC2A1F2BCHEKDM4EALDH1A1 | |
| SCHEMBL30765914 | 0.88 | ELANE (0.39) | ELANESLC2A1F2KDM4EALDH1A1 | |
| SCHEMBL30766090 | 0.84 | ELANE (0.39) | ELANESLC2A1F2KDM4EALDH1A1 | |
| SCHEMBL30765994 | 0.84 | ELANE (0.46) | ELANEF2KDM4EALDH1A1 | |
| SCHEMBL30765687 | 0.84 | BCHE (0.41) | ELANEBCHENPC1RAB9AKDM4E | |
| SCHEMBL30765608 | 0.83 | GAA (0.41) | ELANEBCHENPC1RAB9AAVPR1B | |
| SCHEMBL30765457 | 0.82 | ELANE (0.43) | ELANEF2KDM4EALDH1A1 | |
| SCHEMBL30765773 | 0.82 | ELANE (0.41) | ELANESLC2A1F2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |